van Rhee F, Rosenthal A, Kanhai K, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022;6(16):4773-4781.

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Erratum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173730/
https://www.ncbi.nlm.nih.gov/pubmed/37097712
http://dx.doi.org/10.1182/bloodadvances.2023010152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173730/
https://www.ncbi.nlm.nih.gov/pubmed/37097712
http://dx.doi.org/10.1182/bloodadvances.2023010152

Ejemplares similares